With Compliments

05007557

82-34D06

SOLBECPHARMACEUTICALS LTD

ACN 061 289 218 ABN 85 061 289 218

Unit 1, 298 Selby Street OSBORNE PARK WA 6017 Postal: PO Box 2142 CHURCHLANDS WA 6018 Australia

Phone: +61 8 9446 7555

Fax: +61 8 9446 8777

Email: info@solbec.com.au

www.solbec.com.au





Appendix 3Y Change of Director's Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	SOLBEC PHARMACEUTICALS LTD	
ABN	85 061 289 218	
ſ		

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Anthony William Kiernan	
Date of last notice	28 February 2005	

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Central Manhattan Pty Ltd as trustee of the A W Kiernan Superannuation Fund as to 1,000,000 options	
Date of change	14 – 15 April 2005	
No. of securities held prior to change	975,000 Ordinary Fully Paid Shares 3,500,000 Options	
Class	Ordinary shares and options	
Number acquired	50,000 ordinary shares	
Number disposed	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,250.00	
No. of securities held after change	1,025,000 Ordinary Fully Paid Shares 3,500,000 Options	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Purchase on market of 50,000 ordinary shares	

⁺ See chapter 19 for defined terms.

11/3/2002

